Minovia Therapeutics Announces FDA Clearance of IND Application for a Phase Ib Clinical Trial of MNV-201 in Low Risk Myelodysplastic Syndrome MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria In pre-clinical studies, MNV-201 demonstrated improved...

Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics (Minovia), a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight...

Minovia Therapeutics to Present at Biotech Showcase on Tuesday, January 10, 2023 WOBURN, Mass. and HAIFA, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the Company will be presenting at the...

Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases First in human clinical study provides proof-of-concept for mitochondrial augmentation therapy platform, which enables use of healthy mitochondria to improve mitochondrial function and mitigate...